Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Drugs Design Suppliers In Usa
53 companies found
based inSacramento, CALIFORNIA (USA)
Ainnocence is a next-generation biotech aiming to create a self-evolving modularized intelligent platform that integrates various advanced computational and wet lab technologies to revolutionize the drug discovery and development process. We ...
Simple : CarbonAI searches over 1.9 billion compounds to create synthesizable drug candidates – based only on target sequence. Precise : CarbonAI accurately identifies the most active and safe compound with a multi-objective optimization ...
based inMalmö, SWEDEN
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Oncoral is a novel oral irinotecan tablet in ...
Mangoral is a novel oral imaging agent in development for use in MR-imaging of the liver. Mangoral aims to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with severe kidney ...
based inDaejeon, SOUTH KOREA
We are exploring sequence-based drug discovery and development, which is bypassing the need for 3D structure. ...
Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology. It specializes in genome data analysis, biomarker prediction, molecule selection and optimization. DEARGEN discovers new ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Idiopathic pulmonary fibrosis [IPF] is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the disease progresses, the increased scarring leads to decreasing transfer of oxygen into the bloodstream, and ultimately, ...
based inSan Francisco, CALIFORNIA (USA)
Atomwise is a technology-enabled pharmaceutical company leveraging the power of AI to revolutionize small molecule drug discovery. The Atomwise team invented the use of deep learning for structure-based drug design; this technology underpins ...
based inPak Shek Kok, HONG KONG
Artificial intelligence for every step of pharmaceutical research and development. Our mission is to accelerate drug discovery and drug development by continuously inventing and deploying new artificial intelligence technologies. We provide AI ...
Chemistry42 is an automated machine learning platform for drug design capable of finding novel lead-like structures in ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
OPC1 is an oligodendrocyte progenitor cell therapy that is currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries (SCI). Oligodendrocyte progenitor cells (OPCs) are naturally-occurring precursors to the cells which ...
based inMalvern, PENNSYLVANIA (USA)
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...
based inShirley, NEW YORK (USA)
Creative Biostructure is specialized in providing cost-effective contract services to both academia and biotech/pharmaceutical industries in the field of structural biology and membrane protein technologies. We have developed an all-in-one, ...
based inGermantown, MARYLAND (USA)
VeraChem LLC was founded in 2000 to advance the state of the art in computer-aided drug-discovery and molecular design by developing computational chemistry methods that are based on cutting edge basic science, but are also applicable in applied ...
based inSan Francisco, CALIFORNIA (USA)
The invenious platform aims to enhance safety, efficacy, sterility, value and convenience. BioQ designs ready-to-use delivery systems for hard to prepare and hard to administer infusible drugs – thereby simplifying the infusion process from ...
based inBoston, MASSACHUSETTS (USA)
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Until August 2023, CervoMed was known as ...
Our lead product candidate, Trans sodium crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and ...
based inBozeman, MONTANA (USA)
Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections. Microbion is dedicated to developing ...
Cystic Fibrosis (CF) lung disease, which is estimated to affect more than 30,000 in the US and 70,000 worldwide1, is characterized by chronic bacterial infection and severe inflammation that leads to progressive deterioration in lung function. ...
based inArlington, VIRGINIA (USA)
Your company’s sustainability is our business. With compliance and sustainability measures acting together as a more significant influence on your entire operations-product-chemical management, we believe your intelligence partner should do the ...
based inIthaca, NEW YORK (USA)
MiTeGen designs, manufactures and distributes products for cryo-em (cryo electron microscopy), crystallization, crystallography and X-ray diffraction of proteins, viruses and small molecule/inorganic compounds, and for manipulation and measurement ...
based inFlorida, FLORIDA (USA)
IDenta Corporation, established in 2002, is a leading global provider of chemical detection equipment and forensic testing solutions. Serving law enforcement, military, and government agencies, IDenta delivers innovative tools for detecting illicit ...
based inBerkeley, CALIFORNIA (USA)
InterX, led by Nobel Prize-winning scientists, is developing tools for pharmaceutical ligand design, material science, and biochemistry. We leverage our proprietary software tools for internal molecule development work, as well as joint ventures. ...
InterX Development Division focuses on bridging the risk gap in Drug Discovery from drug targets to novel candidates. The Development Division applies InterX’s proprietary computer-aided drug ...
based inSan Diego, CALIFORNIA (USA)
Capricor is Developing Transformative Cell and Exosome-based Therapeutics for the Treatment and Prevention of Diseases. Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and ...
Our core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. Since ...
based inCarlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of ...
